Stock Watch: Oncology Heritage Impedes Roche's Growth
Telavant Acquisition Is No Slam-Dunk To Turn Around Weak Sales
Once a cancer drug powerhouse, Roche’s newer oncology launches were not taking up the slack caused by biosimilar competition to its former blockbusters. Something else was required.
